Inflammation research needs a disease and a meaningful endpoint
“Anti-inflammatory” is a broad description, not a complete treatment claim. Inflammation can be protective, harmful or both depending on the setting. An experiment showing a change in one…
2 min read · 2 sources→VIP research shows why promising mechanisms need clinical tests
Vasoactive intestinal peptide, or VIP, has biological roles that have motivated research in several disease settings. Aviptadil is a synthetic VIP preparation studied clinically. A…
2 min read · 1 source→Thymalin research requires careful product identification
Thymalin is described in the cited literature as a peptide complex derived from calf thymus. That is an important identity detail: a mixture or extract should not automatically be treated…
2 min read · 1 source→KPV Research Does Not Automatically Validate a Spray
KPV is a short peptide investigated in inflammation research. A primary study examined uptake through the PepT1 transporter in cellular systems and evaluated effects in mouse models of…
2 min read · 3 sources→Thymosin Alpha-1: Clinical Experience Is Not a Universal Benefit Claim
A compound can have a substantial publication history without being proven useful for every proposed purpose. Thymosin alpha-1 is often discussed as an immune-modulating peptide. The…
2 min read · 1 source→Immune Support Claims Need an Outcome, Not a Slogan
The phrase immune support is too broad to evaluate without a defined outcome. Preventing infection, shortening illness, improving vaccine response and treating immune-mediated disease are…
2 min read · 1 source→KPV and Inflammation: What the Transport Experiments Show
KPV is a short peptide investigated in experimental inflammation research. A useful explanation begins with the specific model rather than a claim that it reduces inflammation throughout…
2 min read · 1 source→